The Eric O'Neill lab recently identified a combination of biologically-targeted agents, that could restore epigenetic control and revert squamous pancreatic cancer cells to a more regulated differentiated state.  Although we observe a shift towards normal cell epigenetics, this drug combination is not fully optimised to drive the phenotypic shift. In my research, I am developing and aim to use an innovative data-driven artificial intelligence (AI) approach to delineate novel molecules that can demonstrate improved and robust re-normalisation of epigenetic status and pancreatic differentiation, in order to offer new treatments for this hitherto intractable cancer. A major part of this work is the development of an inverse screening protocol, in order to find the protein targets of small molecules.